Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Cancer Epidemiol Biomarkers Prev. 2022 Dec 5;31(12):2126-2135. doi: 10.1158/1055-9965.EPI-22-0343.
Recent evidence suggests that vitamin D might lower breast cancer mortality. There is also growing interest in vitamin D's potential association with health-related quality-of-life (HRQoL). Associations between circulating 25-hydroxyvitamin D (25OHD) concentrations and HRQoL were examined prospectively among breast cancer survivors at the time of diagnosis and 1 year later.
504 women with incident early-stage breast cancer at Roswell Park Comprehensive Cancer Center were included, and 372 patients provided assessments 1 year later. At each timepoint, participants provided blood samples and completed the SF-36 Health Survey, and surveys on perceived stress, depression, and fatigue. Season-adjusted serum 25OHD concentrations were analyzed in relation to HRQoL measures using multivariable logistic regression models.
Approximately 32% of participants had deficient vitamin D levels at diagnosis, which decreased to 25% at 1 year. Concurrently, although SF-36 physical health summary scores were lower at 1 year, mental health summary scores improved, and levels of depression and perceived stress were lower. In comparison with women with sufficient 25OHD levels (>30 ng/mL) at diagnosis, those who were deficient (<20 ng/mL) had significantly worse HRQoL at diagnosis and 1 year later. Vitamin D deficiency 1 year post-diagnosis was also associated with worse HRQoL, particularly among breast cancer survivors who took vitamin D supplements.
Breast cancer survivors with vitamin D deficiency were more likely to report lower HRQoL than those with sufficient levels at the time of diagnosis and 1 year post-diagnosis.
Our results indicate a potential benefit of vitamin D supplementation for improving breast cancer survivorship.
最近的证据表明，维生素 D 可能降低乳腺癌死亡率。人们对维生素 D 与健康相关生活质量（HRQoL）之间潜在关联的兴趣也在不断增加。本研究前瞻性地分析了诊断时和 1 年后乳腺癌幸存者的循环 25-羟维生素 D（25OHD）浓度与 HRQoL 之间的关系。
罗切斯特大学帕克综合癌症中心的 504 名患有早期乳腺癌的女性患者纳入本研究，其中 372 名患者在 1 年后进行了评估。在每个时间点，参与者提供血液样本并完成 SF-36 健康调查，以及关于感知压力、抑郁和疲劳的调查。使用多变量逻辑回归模型分析季节调整后的血清 25OHD 浓度与 HRQoL 测量之间的关系。
约 32%的参与者在诊断时维生素 D 水平不足，1 年后降至 25%。同时，尽管 1 年后 SF-36 身体健康综合评分较低，但心理健康综合评分有所提高，抑郁和感知压力水平较低。与诊断时 25OHD 水平充足（>30ng/ml）的女性相比，维生素 D 缺乏（<20ng/ml）的女性在诊断时和 1 年后的 HRQoL 显著较差。诊断后 1 年维生素 D 缺乏也与 HRQoL 较差相关，尤其是在服用维生素 D 补充剂的乳腺癌幸存者中。
与诊断时和 1 年后维生素 D 水平充足的患者相比，维生素 D 缺乏的乳腺癌幸存者更有可能报告 HRQoL 较低。
我们的研究结果表明，维生素 D 补充可能有助于改善乳腺癌的生存状况。
